LeMaitre Vascular, Inc. (LMAT)
| Market Cap | 2.16B +15.3% |
| Revenue (ttm) | 256.28M +13.3% |
| Net Income | 62.40M +38.2% |
| EPS | 2.72 +38.1% |
| Shares Out | 22.85M |
| PE Ratio | 34.80 |
| Forward PE | 30.72 |
| Dividend | $1.00 (1.06%) |
| Ex-Dividend Date | May 21, 2026 |
| Volume | 516,099 |
| Open | 94.60 |
| Previous Close | 94.54 |
| Day's Range | 93.21 - 96.47 |
| 52-Week Range | 79.01 - 118.01 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 118.75 (+25.46%) |
| Earnings Date | May 5, 2026 |
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter... [Read more]
Financial Performance
In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $118.75, which is an increase of 25.46% from the latest price.
News
LeMaitre to Participate at Upcoming Investor Conferences in June
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
LeMaitre to Present at the Bank of America Healthcare Conference
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 1...
LeMaitre price target raised to $127 from $118 at Citizens
Citizens analyst Daniel Stauder raised the firm’s price target on LeMaitre (LMAT) to $127 from $118 and keeps an Outperform rating on the shares. LeMaitre continues to demonstrate strong execution,…
LeMaitre price target raised to $120 from $105 at Barrington
Barrington raised the firm’s price target on LeMaitre (LMAT) to $120 from $105 and keeps an Outperform rating on the shares. The firm views the company’s Q1 report as solid.
LeMaitre price target raised to $135 from $110 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on LeMaitre (LMAT) to $135 from $110 and keeps a Buy rating on the shares. After “a clean Q1,” the…
LeMaitre Vascular Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% sales growth, 42% EPS growth, and record results across all major product lines and geographies. Artegraft led with 36% global growth, and guidance was raised for revenue, margins, and EPS for the full year. Cash flow and capital position remain strong.
LeMaitre Vascular Earnings release: Q1 2026
LeMaitre Vascular released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
LeMaitre Vascular Quarterly report: Q1 2026
LeMaitre Vascular has published its Q1 2026 quarterly earnings report on May 5, 2026.
LeMaitre Vascular Slides: Q1 2026
LeMaitre Vascular has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
LeMaitre Q1 2026 Financial Results
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterl...
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after...
LeMaitre Vascular Proxy statement: Proxy filing
LeMaitre Vascular filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
LeMaitre Vascular Proxy statement: Proxy filing
LeMaitre Vascular filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thu...
LeMaitre initiated with a Hold at Freedom Capital
Freedom Capital initiated coverage of LeMaitre (LMAT) with a Hold rating and $113 price target The peripheral vascular surgery focused medtech company has leadership positions in niche markets across ...
LeMaitre to Participate at Upcoming Investor Conferences in March
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.
LeMaitre price target raised to $105 from $95 at Barrington
Barrington raised the firm’s price target on LeMaitre (LMAT) to $105 from $95 and keeps an Outperform rating on the shares. LeMaitre continues to deliver double-digit organic top line growth…
LeMaitre price target raised to $117 from $108 at Roth Capital
Roth Capital raised the firm’s price target on LeMaitre (LMAT) to $117 from $108 and keeps a Buy rating on the shares after its better than expected Q4 results and…
LeMaitre Vascular Slides: Investor presentation
LeMaitre Vascular has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
LeMaitre price target raised to $118 from $113 at Citizens
Citizens raised the firm’s price target on LeMaitre (LMAT) to $118 from $113 and keeps an Outperform rating on the shares. LeMaitre finished the year with top- and bottom-line outperformances,…
LeMaitre Vascular Earnings Call Transcript: Q4 2025
Q4 2025 saw 16% sales growth, 71.7% gross margin, and 47% operating income growth, with strong international expansion and product launches. 2026 guidance projects 12% sales growth, 21% adjusted operating income growth, and continued margin expansion.
LeMaitre Vascular Annual report: Q4 2025
LeMaitre Vascular has published its Q4 2025 annual report on February 25, 2026.
LeMaitre Vascular Earnings release: Q4 2025
LeMaitre Vascular released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
LeMaitre reports Q4 EPS 68c, consensus 66c
Reports Q4 revenue $64.5M, consensus $62.82M. Chairman/CEO George LeMaitre (LMAT) said, “International Artegraft growth, higher ASPs and disciplined spending produced 16% Q4 sales growth and 47% op. i...
LeMaitre Q4 2025 Financial Results
BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarter...